
Sign up to save your podcasts
Or


In part two of our series on the future of ATMPs, Marco Flori, Global Account Manager at Staubli Robotic UK, and Dan Strange, CTO and Co-founder of Cellular Origins, join the podcast to share more about the potential and benefits of automation and robotics in the production of cellular and gene therapies.
By ISPEIn part two of our series on the future of ATMPs, Marco Flori, Global Account Manager at Staubli Robotic UK, and Dan Strange, CTO and Co-founder of Cellular Origins, join the podcast to share more about the potential and benefits of automation and robotics in the production of cellular and gene therapies.